Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com

Articles

Ublituximab/Umbralisib Outperforms Chemoimmunotherapy in Patients with CLL

December 7th 2020

December 7, 2020 — The combination of ublituximab and umbralisib, 2 novel compounds targeting CD20 and PI3Kδ, respectively, has shown synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.

Novel CAR Engineering Overcomes Resistance in Large B-Cell Lymphoma With CD58 Loss

December 5th 2020

December 5, 2020 - Engineering chimeric antigen receptors T cells to overcome CD58 loss may provide a path forward for patients with large B-cell lymphomas who do not respond to treatment with immunotherapy.

Menin Inhibitor Induces Activity in Patients With Refractory AML

December 5th 2020

December 5, 2020 - KO-539, an oral, selective menin-inhibitor, demonstrated activity in patients with relapsed/refractory acute myeloid leukemia in preliminary findings from the ongoing first-in-human KOMET-001 trial.

MLL Fusion Proteins Emerge as a Promising Target in AML

December 3rd 2020

Novel agents that disrupt protein-protein interactions in the MLL network may be the key to unlocking new therapeutic avenues for patients with acute leukemias.

Prognostic Identifiers for ES-SCLC Are Not Revealed in CASPIAN Subgroup Analysis

November 20th 2020

November 20, 2020 - Exploratory subgroup analysis of patients with extensive-stage small-cell lung cancer who derived a progression-free survival benefit with durvalumab plus platinum-based chemotherapy lasting longer than 12 months in the CASPIAN trial did not reveal any clinical characteristics that could serve as predictive factors for benefit with the monoclonal antibody.

Practicing Oncologists Debate New Tactics for Brain Metastases in HER2+ Breast Cancer

October 21st 2020

New approaches for treating patients with HER2-positive metastatic breast cancer are showing signs of efficacy against brain metastases, generating excitement about the potential to make critical advances and sparking questions about optimal sequencing.

Investigators Untangle Emerging Strategies in Gastric Cancer

September 23rd 2020

Findings from clinical trials evaluating HER2-directed and immunotherapeutic approaches for treating patients with gastric cancer are among recent data attracting interest from experts in the gastrointestinal cancer field.

First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC

September 20th 2020

Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival.

Updated Data Shows Xevinapant Significantly Improves OS in Locally Advanced Head and Neck Cancer

September 19th 2020

Three-year follow-up data for the phase 2 study of the first-in-class inhibitor of apoptosis protein antagonist, xevinapant, in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy reduced the risk of mortality by half compared with CRT alone in patients with locally advanced squamous cell carcinoma of the head and neck.

Despite Early Response, Frontline Avelumab Falls Short in Metastatic Urothelial Carcinoma

September 18th 2020

Despite observed responses, induction therapy with avelumab prior to standard of care gemcitabine/carboplatin fails to sustain clinically meaningful efficacy and is not an adequate strategy for the first-line treatment for patients with metastatic urothelial carcinoma.

Cabozantinib Showcases Efficacy in Patients with HCC and Child-Pugh B

September 14th 2020

A retrospective analysis of data from the CELESTIAL trial has demonstrated the potential role for cabozantinib in patients with advanced hepatocellular carcinoma and Child-Pugh B liver cirrhosis.

Subcutaneous Daratumumab Appears Primed to Transform Myeloma Care

August 11th 2020

A new subcutaneous formulation, daratumumab and hyaluronidase-fihj, provides similar efficacy in a more convenient and efficient regimen that is likely to change practice.

Health Equity for Patients With Cancer Requires Moving Conversation to Action

July 31st 2020

In order to achieve health equity for patients with cancer, physicians must first understand the root cause of heath disparities, many of which may be invisible.

Adoptive Cell Therapy Aims to Improve Outcomes in Metastatic Melanoma

July 7th 2020

Lifleucel, a TIL therapy, is being investigated in patients with metastatic melanoma.

Double PIK3CA Mutations in Breast Cancer Increase Sensitivity to PI3Kα Inhibition

June 24th 2020

Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.

Survivin Isoforms Detection Predicts a Potential Role in Tumor Biology

June 22nd 2020

Three main survivin isoforms demonstrated the ability to translocate to the surface of plasma membrane in multiple cell types, suggesting a targetable role as a molecular biomarker.

MGD013 Demonstrates Encouraging Activity Across Tumor Types

June 1st 2020

MGD013, an investigational DART protein targeting PD-1 and LAG-3, demonstrated encouraging monotherapy activity as well as in combination with margetuximab in multiple tumor types.

Belantamab Mafodotin Signals Durable Responses in Relapsed/Refractory Myeloma

May 29th 2020

Single agent belantamab mafodotin sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.

Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets

May 24th 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated continued benefit in patients with HER2-positive breast cancer who had stable, treated brain metastases at baseline.

Low-Intensity Surveillance Demonstrates Utility in NMIBC

May 20th 2020

Low-intensity surveillance may be comparable to high-intensity surveillance for cancer control in patients with high-risk non-muscle invasive bladder cancer.